Search results
GSK Experimental Drug Reduces Severe Asthma Attacks in Key Trial
Bloomberg· 3 days agoAn experimental drug from GSK Plc reduced asthma attacks in late-stage trials, paving the way for a...
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Benzinga via Yahoo Finance· 3 days agoTuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and...
GSK’s asthma drug shows promise in reducing severe attacks
WSAU Wausau· 3 days ago(Reuters) - GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period...
GSK's experimental drug shows promise in reducing severe asthma attacks
Reuters via AOL· 3 days agoThe drug, called depemokimab, showed "significant and meaningful reductions" in asthma attacks for...
Eosinophilic Asthma
Health via Yahoo News· 5 days agoEosinophils are a type of immune system cell...management techniques are necessary. Targeted therapies, such as biologics, are essential for managing...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 2 days agoGSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma...
Manage Your Asthma: FDA on Know Your Triggers and Treatment Options
Sierra Sun Times· 3 days agoAsthma is a chronic lung disease that causes the airways to become inflamed and narrow. Symptoms of...
Asthma Triggers In Homes Can Send Kids to the ER—This Organization Is Working to Change That
Health.com· 3 days agoFor parents of children with asthma, witnessing an attack of severe symptoms can be a terrifying...
Research finds few moderate or severe asthma patients prescribed recommended inhaler regimen
Medical Xpress· 2 days agoIn the United States, ICS-formoterol inhalers include Symbicort (budesonide-formoterol) and Dulera...
GSK boasts win for depemokimab in asthma trials
Clinical Trials Arena via Yahoo Finance· 3 days agoThe pharma giant announced the drug met primary endpoints in both the SWIFT-1 (NCT04719832) and SWIFT-2 (NCT4718103) trials of a reduction in...
